Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Mai 2019 16:05 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments

CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the...
08. Mai 2019 08:30 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy

--Expands pipeline with 6th investigational gene therapy for Limb-girdle muscular dystrophy-- --Furthers the Company’s commitment to finding treatments for neuromuscular conditions-- CAMBRIDGE,...
01. Mai 2019 16:30 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019

CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial...
30. April 2019 18:00 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2019,...
08. April 2019 08:30 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference

CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today stated that its previously announced...
29. März 2019 18:00 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2019,...
28. März 2019 08:30 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study

-- Interim analysis found statistically significant increase in dystrophin production as measured by western blot in casimersen-treated participants compared to baseline and placebo -- -- Based...
25. März 2019 07:30 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program

CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it will host a webcast and...
05. März 2019 19:32 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock

CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has priced an...
05. März 2019 16:02 ET | Quelle: Sarepta Therapeutics, Inc.

Sarepta Therapeutics Announces Proposed $350,000,000 Public Offering of Common Stock

CAMBRIDGE, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it is offering to...

Vorherige Seite